EDAP VS FSTX Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

EDAP
10/100

EDAP returned -58.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

FSTX
100/100

FSTX returned 142.18% in the last 12 months. Based on the other stocks in it's sector with an average return of -26.80%, it's performance is above average giving it a grade of 100 of 100.

Analyst Price Targets

EDAP
75/100

2 analysts offer 12-month price targets for EDAP. Together, they have an average target of 0, the most optimistic target put EDAP at 0 within 12-months and the most pessimistic has EDAP at 0.

FSTX

"Analyst Price Targets" not found for FSTX

Sentiment

EDAP
70/100

EDAP had a bullish sentiment score of 69.60% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 2.46 comments, and 1.77 likes per day.

FSTX
71/100

FSTX had a bullish sentiment score of 71.09% across Twitter and StockTwits over the last 12 months. It had an average of 9.14 posts, 1.03 comments, and 2.06 likes per day.

Technicals

EDAP
14/100

EDAP receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

FSTX
86/100

FSTX receieves a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.

Earnings

EDAP
10/100

EDAP has missed earnings 9 times in the last 20 quarters.

FSTX
19/100

FSTX has missed earnings 3 times in the last 20 quarters.

Profit

EDAP
42/100

Out of the last 20 quarters, EDAP has had 11 profitable quarters and has increased their profits year over year on 4 of them.

FSTX
13/100

Out of the last 20 quarters, FSTX has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

EDAP
53/100

EDAP has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

FSTX
56/100

FSTX has had a higher than average amount of volatility over the last 12 months giving it a grade of 55 of 100.

All score calculations are broken down here to help you make more informed investing decisions

EDAP TMS SA Summary

Nasdaq / EDAP
Healthcare
Medical - Devices
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

F-star Therapeutics, Inc. Common Stock Summary

Nasdaq / FSTX
Healthcare
Biotechnology
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.